Journal
CARCINOGENESIS
Volume 44, Issue 6, Pages 497-510Publisher
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgad028
Keywords
-
Categories
Ask authors/readers for more resources
This study found that solamargine (SM), a natural alkaloid derived from the fruit of Lycium tomato lobelia, inhibits the progression of non-small cell lung cancer (NSCLC) and enhances the anticancer effect of EGFR-TKIs. The mechanism involves the regulation of the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. These findings provide a new strategy and potential candidate targets for overcoming EGFR-TKI resistance in NSCLC.
Lung cancer is the leading cause of cancer-related deaths worldwide. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) showed great therapeutic efficacy for non-small cell lung cancer (NSCLC) patients. However, acquired resistance severely limits the clinical application and efficacy of EGFR-TKIs. In the current study, we found that solamargine (SM), a natural alkaloid derived from the fruit of Lycium tomato lobelia, has been found to inhibit the progression of NSCLC and enhance the anticancer effect of EGFR-TKIs. In brief, SM significantly inhibited the cell viability of NSCLC cells and enhanced the anticancer effect of gefitinib (GFTN) and erlotinib (ERL). Mechanistically, SM decreased the expression of MALAT1 and induced miR-141-3p, whereas reduced SP1 protein levels. Interestingly, both MALAT1 and Sp1 have classical and conservative binding sites of miR-141-3p in their 3MODIFIER LETTER PRIME-UTR regions. Silence of MALAT1 and overexpression of miR-141-3p both decreased the protein expression of Sp1. Subsequently, promoter activity and protein expression of IGFBP1 were upregulated by SM, which was not observed in cells with SP1 overexpression. Moreover, the inhibitory effect of SM on cell growth was significantly blocked by knockdown of IGFBP1 expression. More importantly, the combination of SM and GFTN synergistically inhibited the progression of lung cancer. Similar results were observed in experiments in vivo. Finally, the clinical relevance of MALAT1, Sp1 and IGFBP1 was further validated using bioinformatics analysis. Taken together, we confirmed that SM significantly enhanced the anticancer effect of EGFR-TKIs by regulating the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. This study unravels a novel mechanism and suggests a new potential NSCLC-associated therapy. We revealed that SM suppressed NSCLC progression and enhanced the anticancer effect of EGFR-TKIs including GFTN by regulating the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. This study will provide a new strategy and potential candidate targets for the solution of EGFR-TKIs resistance in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available